All In Biotech

Drug Trial Radar · NCT02572323

Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons

Last checked: Nov 20, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

73

Actual

Start

Feb 15, 2017

Primary completion

Oct 15, 2023

Study completion Oct 15, 2023

Sponsor

Lead sponsor
University of California, San DiegoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Southern California; PalmTree Clinical Research Inc.; University of California, San Francisco
First posted
Oct 8, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to test whether tesamorelin, in combination with a text-messaging application to help with motivation and adherence, will significantly improve memory and thinking in HIV.

Conditions

  • Mild Cognitive Impairment

Interventions

  • TesamorelinDrug

    Tesamorelin is an injectable medication already approved by the U.S. FDA to treat abdominal fat accumulation in HIV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Neurocognitive PerformanceTime frame: Baseline and week 24

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Keck School of Medicine of the University of Southern California

    Los Angeles, California

  • PalmTree

    Palm Springs, California

  • HIV Neurobehavioral Research Program (HNRP)

    San Diego, California

  • University of California, San Francisco

    San Francisco, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.